Top Markets
Coin of the day
Eli Lilly and Company Eli Lilly and Company

Eli Lilly and Company

LLY
株式のランク #14
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
株価
$1,133.97
最終同期: 2026-09-15
時価総額
$1.068T
変化(1日)
-0.39%
変化(1年)
48.29%
US
取引 Eli Lilly and Company (LLY)

カテゴリー

Eli Lilly and Company(LLY)の株価履歴
終値の最高値: $1.14K (2026-09-01)

終値の最安値: $2.77 (1970-07-01)
Eli Lilly and Company の株価履歴(1970 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -2.13%
2025 32.01%
2024 36.13%
2023 59.08%
2022 40.15%
2021 62.28%
2020 28.57%
2019 11.15%
2018 30.99%
2017 21.80%
2016 -17.45%
2015 20.78%
2014 40.74%
2013 2.24%
2012 22.60%
2011 15.15%
2010 -3.80%
2009 -0.25%
2008 -32.47%
2007 0.97%
2006 -3.69%
2005 -1.19%
2004 -21.27%
2003 9.52%
2002 -19.84%
2001 -10.68%
2000 33.80%
1999 -22.72%
1998 32.51%
1997 76.25%
1996 43.02%
1995 65.62%
1994 9.23%
1993 -8.67%
1992 -18.33%
1991 3.95%
1990 13.36%
1989 49.67%
1988 22.36%
1987 -4.39%
1986 40.68%
1985 64.97%
1984 11.03%
1983 1.08%
1982 4.75%
1981 -6.12%
1980 -3.33%
1979 32.54%
1978 22.82%
1977 -18.99%
1976 -13.66%
1975 -17.90%
1974 -12.93%
1973 -2.40%
1972 33.07%
1971 14.37%
1970 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$266.40 50.97%
US
$262.41 21.34%
US
$477.83 37.52%
CH
$143.68 77.19%
US
$147.59 19.79%
CH